|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-8-15
|
|
pubmed:abstractText |
We sought to determine the response rate and toxicity profile of sequential paclitaxel and bryostatin-1, a novel, selective inhibitor of protein kinase C, in patients with advanced esophageal cancer.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
875-80
|
|
pubmed:meshHeading |
pubmed-meshheading:18270704-Adenocarcinoma,
pubmed-meshheading:18270704-Adult,
pubmed-meshheading:18270704-Aged,
pubmed-meshheading:18270704-Antineoplastic Agents,
pubmed-meshheading:18270704-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:18270704-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18270704-Bryostatins,
pubmed-meshheading:18270704-Carcinoma, Squamous Cell,
pubmed-meshheading:18270704-Disease Progression,
pubmed-meshheading:18270704-Esophageal Neoplasms,
pubmed-meshheading:18270704-Female,
pubmed-meshheading:18270704-Humans,
pubmed-meshheading:18270704-Male,
pubmed-meshheading:18270704-Middle Aged,
pubmed-meshheading:18270704-Paclitaxel
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer.
|
|
pubmed:affiliation |
Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|
